section name header

Evidence summaries

Blood Pressure Lowering Efficacy of Renin Inhibitor Aliskiren for Primary Hypertension

Renin-inhibitor aliskiren appears to have a dose-related blood pressure lowering effect better than placebo and similar to that determined for ACE inhibitors and angiotensin receptor blockers (ARBs). Level of evidence: "B"

The quality of evidence is downgraded by study limitations (differential loss to follow-up in the compared groups).

Summary

A Cochrane review [Abstract] 1 included 12 studies with a total of 7 439 mostly Caucasian subjects with mild-to-moderate uncomplicated hypertension (mean age 54 years). Aliskiren (the only renin inhibitor studied) had a dose-related systolic/diastolic blood pressure (SBP/DBP) lowering effect as compared with placebo: aliskiren 75 mg (MD -2.97, 95% CI -4.76 to -1.18)/(MD -2.05, 95% CI -3.13 to -0.96) mmHg, aliskiren 150 mg (MD -5.95, 95% CI -6.85 to -5.06)/(MD -3.16, 95% CI -3.74 to -2.58) mmHg, aliskiren 300 mg (MD -7.88, 95% CI -8.94 to -6.82)/(MD -4.49, 95% CI -5.17 to -3.82) mmHg, aliskiren 600 mg (MD -11.35, 95% CI -14.43 to -8.27)/(MD -5.86, 95% CI -7.73 to -3.99) mmHg. There was a dose-dependent decrease in blood pressure for aliskiren 75 mg, 150 mg and 300 mg. The blood pressure lowering effect of aliskiren 600 mg was not different from 300 mg. Aliskiren had no effect on blood pressure variability. Mortality and non-fatal serious adverse events were not increased. In studies of 8 week duration aliskiren did not increase withdrawal due to adverse events. The most frequent adverse events reported were headache, nasopharyngitis, diarrhoea, dizziness and fatigue. Diarrhoea was increased in a dose-dependent manner (RR 7.00, 95% CI 2.48 to 19.72) with aliskiren 600 mg.

    References

    • Musini VM, Lawrence KA, Fortin PM et al. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 2017;(4):CD007066. [PubMed]

Primary/Secondary Keywords